Eledon Pharmaceuticals Announces Upcoming Presentations on AT-1501 at the Virtual 2021 American Transplant Congress
The abstracts and additional information can be found on the ATC website at https://atcmeeting.org.
ORAL PRESENTATIONS
Title: A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-1501
- Date and Time:
Monday, June 7 ,6:00 PM –6:05 PM EST - Presenter:
Steven Perrin , Ph.D.,Eledon Pharmaceuticals - Session Title: Kidney Immunosuppression
- Abstract: 273
- Date and Time:
Tuesday, June 8 ,6:05 PM –6:10 PM EST - Presenter:
Norma Sue Kenyon , Ph.D., Professor of Surgery, Microbiology & Immunology and Biomedical Engineering,University of Miami ,Miami, FL - Session Title: Xenotransplantation and Preclinical Studies
- Abstract: 343
POSTER PRESENTATIONS
Title: Pharmacokinetic and Toxicity Studies of an Anti-CD40L Antibody, AT-1501 in Rhesus Macaques
- Presenter:
Steve Perrin , Ph.D.,Eledon Pharmaceuticals - Session Title: Acute Rejection
- Abstract: 506
Title: The Development and Characterization of AT-1501, an Anti-CD40L Antibody Lacking Fc Effector Function
- Presenter:
Steven Perrin , Ph.D.,Eledon Pharmaceuticals - Session Title: Antigen Presentation/Allorecognition/Dendritic Cell
- Abstract: 512
About
Follow
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, the company’s capital resources and ability to finance planned clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sides, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of the company’s capital resources to fund planned clinical trials; and risks associated with the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the
Investor Contact:
cdavis@lifesciadvisors.com
212.915.2577
Source:
Source: Eledon Pharmaceuticals, Inc.